28 October 2020
The new technology and innovation centre is set to become a unique and world-leading facility offering transformative solutions in small molecule and pharmaceutical manufacturing. It will accelerate the development and industrialisation of next-generation medicines manufacturing innovations and maximise technology opportunities within the medicines supply chain. Industry, academia, healthcare providers and regulators will work collaboratively within a GMP environment to address industry challenges and de-risk new technologies, providing a clear pathway for their widespread adoption within the pharmaceutical industry.
The Medicines Manufacturing Innovation Centre is a collaboration between CPI, the University of Strathclyde and founding industry partners, GSK and AstraZeneca with funding provided by Scottish Enterprise and UK Research and Innovation. The Centre has recently agreed partnerships with four leading technology companies to further strengthen the range of expertise in the collaboration.
The facility will translate, at industrial and commercial scale, novel techniques for producing patient-centric medicines, including real-time release of drugs, and integrated process analytics to drive the transformation of medicines manufacturing. These technologies will enable a reduction in quantities of the materials currently required in process development; accelerate timelines to achieve just-in-time, right-first-time and real-time-release manufacturing principles; and ultimately accelerate access of affordable medicines for healthcare providers and patients.
Companies of all sizes will be able to use the facility to evaluate, test and prototype processes using an array of advanced Industry 4.0 manufacturing technologies, including continuous, digital and autonomous manufacturing. The utilisation of next-generation technology will enable more efficient drug production to protect future generations by bringing new medicines to market safely and quickly.
The facility is due for completion late 2021 and will be operational in early 2022. It is expected to eventually house over 80 staff in both technical and non-technical roles.
Nadhim Zahawi, Life Sciences Minister, said: “Backed with £13 million of government funding, this centre is the first of its kind and will significantly boost our domestic medicines manufacturing capability to ensure we are prepared for any future health crises. Complementing our state of the art Vaccines Manufacturing Innovation Centre in Oxfordshire, it will ensure we are at the forefront of transformational technologies, attracting tens-of-millions-of-pounds of investment to the UK and creating new highly-skilled jobs in the Renfrewshire area – a great example of how we are working to build back better.”
Ivan McKee, Scottish Government Minister for Trade, Investment and Innovation, said: “The Medicines Manufacturing Innovation Centre is a tremendous boost to the Scottish economy, and a great endorsement of Scotland’s strengths in life and chemical sciences. The Scottish Government is committed to attracting inward investment from global partners, whose investment in this project will help to create highly skilled jobs in Scotland in a vitally important sector. As an integral part of the Advanced Manufacturing Innovation District Scotland, the centre will put Scotland at the cutting edge of advanced pharmaceutical manufacturing, developing innovative technologies which will help to strengthen the pharmaceutical supply chain.”Print
04 December 2020
03 December 2020
03 December 2020
02 December 2020